KPMA urged to come up with countermeasures over price-cut plan and KORUS FTA

Published: 2012-02-28 07:00:00

Updated: 2012-02-28 07:00:00

The new executives of the Korea Pharmaceutical Manufacturers Association needs to assess the damage that the government’s impending price-cut plan and Korea’s free trade deals with the U.S. would cause in the pharmaceutical industry sector in the future and map out proper countermeasures, industr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK